JP2020204489A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020204489A5 JP2020204489A5 JP2019111310A JP2019111310A JP2020204489A5 JP 2020204489 A5 JP2020204489 A5 JP 2020204489A5 JP 2019111310 A JP2019111310 A JP 2019111310A JP 2019111310 A JP2019111310 A JP 2019111310A JP 2020204489 A5 JP2020204489 A5 JP 2020204489A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- pulmonary fibrosis
- idiopathic pulmonary
- binds
- prognosis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims 7
- 208000036971 interstitial lung disease 2 Diseases 0.000 claims 7
- 238000004393 prognosis Methods 0.000 claims 5
- 238000000034 method Methods 0.000 claims 4
- 102000004169 proteins and genes Human genes 0.000 claims 4
- 108090000623 proteins and genes Proteins 0.000 claims 4
- 102100023774 Cold-inducible RNA-binding protein Human genes 0.000 claims 3
- 101000906744 Homo sapiens Cold-inducible RNA-binding protein Proteins 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 239000012472 biological sample Substances 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 210000004072 lung Anatomy 0.000 claims 1
- 239000013642 negative control Substances 0.000 claims 1
- 239000013641 positive control Substances 0.000 claims 1
- 210000002966 serum Anatomy 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 238000002054 transplantation Methods 0.000 claims 1
Claims (5)
- 下記（ａ）～（ｃ）の工程を含む、特発性肺線維症の予後を判定する方法
（ａ）被検体から分離された生体試料について、ＣＩＲＰ、１４－３－３γ及びＳ１００Ａ４から選択される少なくとも１のタンパク質の量を検出する工程、
（ｂ）工程（ａ）で検出したタンパク質量を各タンパク質の基準量と比較する工程、
（ｃ）工程（ｂ）における比較の結果、前記被検体におけるタンパク質量が基準発現量よりも高い場合、前記被検体の特発性肺線維症の予後は不良であると判定する工程。 - 前記生体試料が血清である、請求項１に記載の方法。
- 請求項１又は２に記載の方法により、特発性肺線維症の予後を判定するための薬剤であって、ＣＩＲＰに結合する抗体、１４－３－３γに結合する抗体及びＳ１００Ａ４に結合する抗体から選択される少なくとも１の抗体を含む薬剤。
- 請求項１又は２に記載の方法により特発性肺線維症の予後は不良であると判定された被検体に対して、特発性肺線維症の治療薬を投与する、及び／又は、肺移植を施す、特発性肺線維症の治療方法。
- ＣＩＲＰに結合する抗体、１４－３－３γに結合する抗体及びＳ１００Ａ４に結合する抗体から選択される少なくとも１の抗体と、前記抗体に対するアイソタイプコントロール抗体、陽性対照及び陰性対照から選択される少なくとも１の物品とを含む、特発性肺線維症の予後を判定するためのキット。
Priority Applications (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2019111310A JP7300642B2 (ja) | 2019-06-14 | 2019-06-14 | 特発性肺線維症の予後予測方法 |
| CN202080043406.1A CN114026429A (zh) | 2019-06-14 | 2020-06-12 | 特发性肺纤维化症的预后预测方法 |
| EP20821764.6A EP3985396A4 (en) | 2019-06-14 | 2020-06-12 | IDIOPATHIC PULMONARY FIBROSIS PROGNOSTIC PREDICTION METHOD |
| US17/618,553 US20220357344A1 (en) | 2019-06-14 | 2020-06-12 | Prognosis prediction method of idiopathic pulmonary fibrosis |
| PCT/JP2020/023227 WO2020251024A1 (ja) | 2019-06-14 | 2020-06-12 | 特発性肺線維症の予後予測方法 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2019111310A JP7300642B2 (ja) | 2019-06-14 | 2019-06-14 | 特発性肺線維症の予後予測方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020204489A JP2020204489A (ja) | 2020-12-24 |
| JP2020204489A5 true JP2020204489A5 (ja) | 2022-06-14 |
| JP7300642B2 JP7300642B2 (ja) | 2023-06-30 |
Family
ID=73782031
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019111310A Active JP7300642B2 (ja) | 2019-06-14 | 2019-06-14 | 特発性肺線維症の予後予測方法 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20220357344A1 (ja) |
| EP (1) | EP3985396A4 (ja) |
| JP (1) | JP7300642B2 (ja) |
| CN (1) | CN114026429A (ja) |
| WO (1) | WO2020251024A1 (ja) |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5667981A (en) * | 1994-05-13 | 1997-09-16 | Childrens Hospital Of Los Angeles | Diagnostics and treatments for cancers expressing tyrosine phosphorylated CRKL protein |
| AU2006227776A1 (en) * | 2005-03-18 | 2006-09-28 | Institute For Chemical Genomics | Alpha-helix mimetics and methods relating to the treatment of fibrosis |
| EA201590630A1 (ru) * | 2012-10-30 | 2015-10-30 | Джилид Сайэнс, Инк. | Способы лечения и диагностики, связанные с лизилоксидазоподобным белком 2 (loxl2) |
| GB201219487D0 (en) * | 2012-10-30 | 2012-12-12 | Cancer Rec Tech Ltd | Anti-S100A4 antibody molecules and their uses |
| EP3252169B1 (en) * | 2013-02-14 | 2022-04-06 | The Regents Of The University Of Colorado | Methods for predicting risk of interstitial pneumonia |
| BR112015023699A2 (pt) * | 2013-03-15 | 2017-07-18 | Intermune Inc | método de determinação de um nível de expressão de uma proteína marcadora de doença pulmonar fibrótica, método de determinação se um indivíduo tem ou está em risco de desenvolvimento de uma doença pulmonar fibrótica, método de determinação se um paciente de doença pulmonar fibrótica está em risco de progressão da doença pulmonar fibrótica, método de determinação de uma atividade de doença pulmonar fibrótica em um paciente, e método de tratamento de uma doença pulmonar fibrótica em um indivíduo em necessidade do mesmo |
| JP2018127443A (ja) * | 2017-02-09 | 2018-08-16 | 国立大学法人山形大学 | ヒト抗ｆｘｉｉｉ（ｆ１３、凝固第ｘｉｉｉ因子）−ａモノクローナル抗体 |
-
2019
- 2019-06-14 JP JP2019111310A patent/JP7300642B2/ja active Active
-
2020
- 2020-06-12 CN CN202080043406.1A patent/CN114026429A/zh active Pending
- 2020-06-12 US US17/618,553 patent/US20220357344A1/en active Pending
- 2020-06-12 EP EP20821764.6A patent/EP3985396A4/en active Pending
- 2020-06-12 WO PCT/JP2020/023227 patent/WO2020251024A1/ja active Application Filing
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016519763A5 (ja) | ||
| JP2017113019A5 (ja) | ||
| JP2017538671A5 (ja) | ||
| JP2016020389A5 (ja) | ||
| JP2013500941A5 (ja) | ||
| JP2014518883A5 (ja) | ||
| JP2017517745A5 (ja) | ||
| JP2012509477A5 (ja) | ||
| JP2018148931A5 (ja) | ||
| JP6918005B2 (ja) | 細胞内抗原に対して向けられた単一ドメイン抗体 | |
| JP2018516244A5 (ja) | ||
| JP2017039729A5 (ja) | ||
| JP2014515740A5 (ja) | ||
| Sciurba et al. | Fibroblast‐specific integrin‐alpha V differentially regulates type 17 and type 2 driven inflammation and fibrosis | |
| Zhang et al. | A comparison of telbivudine and entecavir in the treatment of hepatitis B e antigen-positive patients: a prospective cohort study in China | |
| Zhu et al. | Prediction model for sustained hepatitis B e antigen seroconversion to peginterferon alfa‐2a in chronic hepatitis B | |
| JP2016528914A5 (ja) | ||
| JP2020204489A5 (ja) | ||
| Siegl et al. | Using the one-lung method to link p38 to pro-inflammatory gene expression during overventilation in C57BL/6 and BALB/c mice | |
| JP2007531733A5 (ja) | ||
| Pechous et al. | An ex vivo human precision-cut lung slice platform provides insight into SARS-CoV-2 pathogenesis and antiviral drug efficacy | |
| Chen et al. | Captopril decreases plasminogen activator inhibitor-1 in rats with ventilator-induced lung injury | |
| JP2019526810A5 (ja) | ||
| Lin et al. | Telbivudine and adefovir combination therapy for patients with chronic lamivudine-resistant hepatitis B virus infections | |
| JP2017522890A5 (ja) |